Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
Slika profila

Sanja Giljanović Kiš

9829

Sanja

Giljanović Kiš

mr. sc.

dr.med

M.D., MSc

nije evidentirano
Naziv Akcije
Monteiro, Pedro ; Bergenstal, M. Richard ; Toural, Elvira ; Inzucchi, E. Silvio ; Zinman, Bernard ; Hantel, Stefan ; Giljanovic Kiš, Sanja ; Kaspers, Stefan ; George, T. Jyothis ; Fitchett, David Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial // Age and ageing, 48 (2019), 6; 859-866. doi: 10.1093/ageing/afz096
Giljanovic Kis, Sanja ; Khunti, Kamlesh ; Maldonado, Mario ; Del Parigi, Angelo ; Götz, Sophia ; Lee, Christopher Linagliptin (LINA) as Add-on to Empagliflozin (EMPA) and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Baseline Demographics in Two 24-Week Randomized, Double Blind, Parallel-Group Trials // Diabetes (New York, N.Y.). 2016. str. A297-A297
RIDDERSTRÅLE, MARTIN ; TOURAL, ELVIRA ; FITCHETT, DAVID ; GILJANOVIC KÎS, SANJA ; WOERLE, HANS JURGEN ; MATTHEUS, MICHAELA ; ZINMAN, BERNARD ; INZUCCHI, SILVIO E. Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG OUTCOME® // Diabetes (New York, N.Y.). 2016
Romera, Irena ; Ampudia-Blasco, Francisco Javier ; Pérez, Antonio ; Arino, Bernat ; Pfarr, Egon ; Giljanović Kis, Sanja ; Naderali, Ebrahim Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus // Endocrinología y nutrición, 63 (2016), 10; 519-526. doi: 10.1016/j.endonu.2016.06.003
Romera, Irene ; Gomis, Ramon ; Crowe, Susanne ; de Pablos-Velasco, Pedro ; Aranda, Unai ; García, Arantxa ; Giljanovic Kis, Sanja ; Naderali, Ebrahim Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials // Journal of diabetes and its complications, 30 (2016), 8; 1571-1576. doi: 10.1016/j.jdiacomp.2016.07.016
Roden, Michael ; Lund, Soeren ; Pfarr, Egon ; Kohler, Sven ; Naderali, Ebrahim ; Giljanovic Kiš, Sanja Efficacy and safety of empagliflozin by baseline age in patients with type 2 diabetes // IDF 2015: Abstracts. 2015. str. Abstract:0368-PD-x
Muačević-Katanec, Diana ; Sertić, Jadranka ; Giljanović, Sanja ; Miličević, Zvonimir ; Metelko, Željko ; Stavljenić-Rukavina, Ana Utjecaj polimorfizma apolipoproteina E na terapijski odgovor u bolesnika s hiperlipoproteinemijom // Liječnički vjesnik. Zagreb, 1998. str. 21-x
Giljanović, Sanja ; Muačević-Katanec, Diana ; Miličević, Zvonko ; Metelko, Željko Određivanje ranih hormonskih i metaboličkih čimbenika rizika za razvoj koronarne bolesti u mlađih muškaraca s abdominalnim tipom pretilosti. Hrvatski liječnički zbor, 1998
Huić, Mirjana ; Vrhovac, Božidar ; Francetić, Igor ; Bakran, Ivan ; Giljanović, Sanja How safe are bioequivalence studies in healthy volunteers? // Therapie, 51 (1996), 410-413
Giljanović, Sanja ; Mikuš, D. Sikirić, Predrag ; Seiwerth, Sven ; Grabarević, Željko ; Ručman, Rudolf ; Petek, Marijan ; Miše, Maja ; Rotkvić, Ivo ; Turković, Branko ; Jagić, Vjekoslav et al. Pentadecapeptide BPC 157 and rantidine have cytoprotective property. An effect in chronic stomach ulcers and cysteamine-duodenal ulcers in normal and gastrectomized rats // Abstracts of the Fourth Congress of the International Brain-Gut Society. Pečuh: Hungarian Academy of Sciences (MTA), 1996. str. 15-15
nije evidentirano
nije evidentirano